AbbVie Stock

AbbVie Debt

The Debt of AbbVie (ABBV) as of Sep 15, 2026 is 67.14 B USD. In the previous year, Debt was 59.39 B USD — a change of 13.07% (higher).

Debt

67.14 BUSD

YoY

13.07%

Last updated:

In 2026, AbbVie's total debt was 67.14 B USD, a 13.07% change from the 59.39 B USD total debt recorded in the previous year.

The AbbVie Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
37.37 B USD
Jan 1, 2018
40.31 B USD
Jan 1, 2019
66.73 B USD
Jan 1, 2020
86.06 B USD
Jan 1, 2021
76.68 B USD
Jan 1, 2022
63.27 B USD
Jan 1, 2023
59.39 B USD
Jan 1, 2024
67.14 B USD
The AbbVie Debt history
YEARDebtYoY
67.14 BUSD+13.07%
59.39 BUSD-6.14%
63.27 BUSD-17.49%
76.68 BUSD-10.89%
86.06 BUSD+28.97%
66.73 BUSD+65.54%
40.31 BUSD+7.87%
37.37 BUSD+1.43%
36.84 BUSD+16.33%
31.67 BUSD+111.46%
14.98 BUSD
Access this data via the Eulerpool API

AbbVie Stock analysis

What does AbbVie do? Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie is one of the most popular companies on Eulerpool.

Debt Details

Understanding AbbVie's Debt Structure

AbbVie's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing AbbVie's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to AbbVie’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in AbbVie’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about AbbVie stock

Debt of AbbVie is 67.14 B USD in 2026.

Debt of AbbVie changed from 59.39 B USD to 67.14 B USD, representing a 13.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt AbbVie since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's AbbVie historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AbbVie

All Key Metrics — AbbVie